Analogic Corporation

Analogic — Investor Presentation (March 2017)

38 slides from Analogic's investor presentation, Mar 15, 2017

  1. Slide 1: Investor overview

    Investor overview March 15, 2017 Exhibit 99.1

  2. Slide 2: Safe Harbor

    Safe Harbor Any statements about future expectations, plans, and prospects for the Company, including statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation

  3. Slide 3: Use of Non-GAAP Financial Measures

    This presentation includes non-GAAP financial measures that are not in accordance with, nor an alternative to, generally accepted accounting principles and may be different from such non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive se

  4. Slide 4: Years of Imaging Innovation

    50 Years of Imaging Innovation Founded in 1967 Advancing image guidance technology for medical and security Global research, engineering, and operations Fiscal 2016 Highlights: $509 million revenue $3.54 Non-GAAP* EPS Operating cash of $33 million, Free cash flow** of $20 million 1,500 employees wor

  5. Slide 5: Our Imaging Technology Drives Innovative Products

    Our Imaging Technology Drives Innovative Products Material Science Signal and image processing Precision A/D conversion Precision RF/Power Amplification Imaging & Guidance “Core Technologies” “Critical Imaging Chain” Mammo Ultrasound Probes High voltage power supplies High power amplifiers Pulsed RF

  6. Slide 6: Our Business Segments

    Our Business Segments Medical Imaging Ultrasound Security & Detection 57% of revenues* 32% of revenues* 11% of revenues* Increase content with OEMs Leverage common platforms Drive growth in emerging markets Focus in Urology and Surgery Expand into General Imaging with technology partner Exploit oppo

  7. Slide 7: Moving to the Next Level of Performance

    Moving to the Next Level of Performance Non-GAAP operating margin and non-GAAP EPS figures exclude certain charges; please refer to the non-GAAP reconciliation table in the back of this presentation. Inconsistent results in recent years requires renewed focus

  8. Slide 8: Ultrasound

    ULTRASOUND

  9. Slide 9: FY2017 Ultrasound Restructuring

    FY2017 Ultrasound Restructuring 90 day assessment of Ultrasound has been completed Objective Plan Resize expense structure to align with growth opportunities Define new Leadership structure in Ultrasound Consolidate R&D and service with closing of Vancouver Optimize manufacturing, sales, marketing a

  10. Slide 10: Focused Ultrasound Market Opportunities

    Focused Ultrasound Market Opportunities Global Ultrasound Market 2016 ($6.4 billion) 1 POC – Point of care 2 EMED: Emergency Medicine Revenue Growth Rate by Application (’15-’20) BK Ultrasound Markets ($0.6B) Partner Markets ($3B) Source: IHS 2016 Oncura Market ($0.2B) Technology Partnerships Focuse

  11. Slide 11: Portfolio Optimization

    Portfolio Optimization *Analogic Patented and Trademarked Technology Surgical Guidance bk5000 Urology bk3000 General Imaging Partnerships Point of Care Anesthesia/EMED Handheld and Vet bk3500 Portfolio Optimization

  12. Slide 12: Ultrasound: Turnaround Opportunity

    Ultrasound: Turnaround Opportunity Sales growth has not matched our pace of investment Focus on optimizing portfolio and improving operating profit FY17 and FY18 estimates are based on mid-point of range Non-GAAP operating margin and non-GAAP EPS figures exclude certain charges; please refer to the

  13. Slide 13: Medical Imaging

    Medical Imaging

  14. Slide 14: Guidance in Medical Imaging

    Guidance in Medical Imaging Computed Tomography Digital Mammography Magnetic Resonance

  15. Slide 15: Increasing Value with Full Systems

    Increasing Value with Full Systems Data Acquisition Subsystem Detection Management Subsystem Power & Data Management CT Imaging engine Image Reconfiguration GE OPTIMA NM/CT 640 Accuray TomoTherapy Anke 16-Slice CT

  16. Slide 16: Ruggedized CT Gantry Installations

    Qinghai Xinjiang Inner Mongolia Tibet Guizhou Zhejiang Fujian Gansu Ningxia Shanxi Shanxi Hebei Heilongjiang Jilin Liaoning Shandong Jiangsu Henan Anhui Hubei Hunan Jiangxi Yunnan Sichuan Chongqing Guangxi Guangdong Ruggedized CT Gantry Installations Beijing > 185 installed through Feb. 2017

  17. Slide 17: Magnetic Resonance Power Sub-systems

    Magnetic Resonance Power Sub-systems RF Amplifier Gradient Amplifier Enabled 3T wide bore systems Common platforms and modular design Design wins with new market entrants

  18. Slide 18: Digital Mammography Detector Sub-Systems

    Digital Mammography Detector Sub-Systems Analogic Enables Best Detection Superior Se Based Technology Premium 3D tomo performance Lower dose with best image quality Fastest Image acquisition US installed base of 2D is ~ 11,000 systems, more than 5000 are 7+ years Replacement cycle is moving to 3D

  19. Slide 19: Medical Imaging: Solid Profitability

    Medical Imaging: Solid Profitability OEM sourcing decisions effect short term revenue growth Margin improvement driven by product/customer mix and cost initiatives FY17 estimates are based on mid-point of range Non-GAAP operating margin and non-GAAP EPS figures exclude certain charges; please refer

  20. Slide 20: Security and Detection

    Security and Detection

  21. Slide 21: Checked Baggage Opportunities with Leading OEMs

    Checked Baggage Opportunities with Leading OEMs North America Replacement Demand 1800 sockets TSA extended EDS life from 10 to 15 years to prepare for next gen purchases Canada completing purchases of high-speed EDS systems Europe and Middle East Increasing Momentum 2000 sockets Early adoption under

  22. Slide 22: Checkpoint CT Under Evaluation

    Checkpoint CT Under Evaluation ConnectCT accepted into TSA laboratory for formal certification testing; International certification testing in early 2017 Commercial trials with CT in Europe validated a 2X operational improvement with over 1.3 million bags scanned while improving detection ConnectCT

  23. Slide 23: Upside Potential in Rapid DNA

    Upside Potential in Rapid DNA DNA profile generated in under 84 minutes vs. weeks in federal labs Significant market opportunity for law enforcement and government agencies FBI NDIS (National DNA Index System) approval achieved for domestic 4-color version Evaluation currently underway for new globa

  24. Slide 24: Security and Detection: Strong Leverage

    Security and Detection: Strong Leverage Revenue growth driven by international high speed tenders and upside with Checkpoint CT and RapidDNA Strong double digit revenue growth Mid-teens non-GAAP operating margins FY17 estimates are based on mid-point of range Non-GAAP operating margin and non-GAAP E

  25. Slide 25: Financial Outlook

    F SIPINANCIAL =. OUTLOOK

  26. Slide 26: Financial Outlook

    Financial Outlook FY17 - Expect flat revenue growth with non-GAAP operating margin between 10.0% and 11.5% resulting in non-GAAP diluted EPS of between $3.00 and $3.45 Fiscal 2018 - Total company revenues expected to be down low-single digits with Non-GAAP operating margins up approximately 1 point.

  27. Slide 27: Strong Balance Sheet and Consistent Cash Flows

    Strong Balance Sheet and Consistent Cash Flows 1 As of July 31, 2015 Includes $12MM tax refund $153M1 of cash/investments with no long term debt - YTD operating cash flow of $41M, Free cash flow of $35M Capital allocation through ongoing investment, M&A and share re-purchase $15 million share repurc

  28. Slide 28: Appendix

    Appendix OVERVIEW

  29. Slide 29: Q2 FY17 Financial Highlights

    Q2 FY17 Financial Highlights Strength in Security Offset by Ultrasound and Medical Imaging * Non-GAAP operating margin/income figures exclude certain charges; please refer to the non-GAAP reconciliation table in the back of this presentation and in Analogic’s Q2 FY 2017 earnings release available at

  30. Slide 30: Revenue and Non-GAAP Operating Margin Trend

    FY17 FY16 Revenue $M and Non-GAAP* Operating Margin Trend Non-GAAP Operating Margin* Non-GAAP OM 16% 21% 18% 20% 12% 20% GAAP OM 10% 16% 14% 17% 10% 17% 10% 9% 19% 16% 18% 15% 2% -2% 14% 11% 17% 9% FY17 FY16 -5% 7% -5% 4% -11% -2% -13% -23% -13% -2% -16% -11% Operating Performance by Segment Medical

  31. Slide 31: Working Capital and Cash Flow

    Working Capital and Cash Flow (Amounts may not foot due to rounding to millions) Operating cash flow of $14M in Q2, Cap Ex at $2M resulting in Free cash flow of $12M Accounts receivables lower driving DSO down by 3 days sequentially to 53 days Inventory down $2M sequentially on higher volume of ship

  32. Slide 32: FY17 and Long Term Outlook

    FY17 and Long Term Outlook FY17 - Expect flat revenue growth with non-GAAP operating margin between 10.0% and 11.5% resulting in non-GAAP diluted EPS of between $3.00 and $3.45 Ultrasound: Mid-single digits revenue declines with negative low-single digit op margin Restructuring actions will disrupt

  33. Slide 33: Non-GAAP Reconciliation

    Non-Gaap Reconciliation Gi \ OVERVIEW analogic” ‘

  34. Slide 34: Non-GAAP Statements of Operations Reconciliation

    NON-GAAP ST’ ME (hn thousands, excopt per share data) GAAP Income From Operation: Rost ‘Acquistion rolated revenues and expenses Non-GAAP Income From Operations Percentage of Total Net Revenue GAAP Other income (Expen: don BK Medical distrbutor mattor inquiry related costs ‘Acquisition rolated reven

  35. Slide 35: Non-GAAP Statements of Operations Reconciliation

    NON-GAAP STATEMENTS OF OPERATIONS RECONCILIATION (h thousands, except per share data) ‘Twelve months Ended July 34,2012 July 34,2013 July 31,2014 July 31,2015 July31, 2016 Medical Imaging GAAP Income From Operations Shore sation expense “ax refund related cha GAAP Income From Operations " Percentage

  36. Slide 36: Non-GAAP Statement of Operations Reconciliation

    Non-GAAP Statement of Operations Reconciliation (Amounts may not foot due to rounding to millions)

  37. Slide 37: Non-GAAP Statement of Operations Reconciliation

    Non-GAAP Statement of Operations Reconciliation (Amounts may not foot due to rounding to millions)

  38. Slide 38: Non-GAAP Segment Financial Reconciliation

    Non-GAAP Segment Financial Reconciliation (Amounts may not foot due to rounding to millions)

Analogic — Investor Presentation (March 2017) on 6ix